Zealand Pharma A/S (ZLDPY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Zealand Pharma used the Goldman Sachs Healthcare Conference to highlight post-ADA progress on survodutide and petrelintide, with management saying the obesity market is shifting toward minimum effective dosing. The commentary was broadly constructive but contained no new quantitative clinical or regulatory data. The update is informative for sentiment around the pipeline, but likely limited immediate price impact.

Analysis

The market is increasingly rewarding obesity assets that can credibly shift the efficacy narrative from “highest dose wins” to “best therapeutic window wins.” That favors Zealand’s platform if management can keep positioning around differentiated tolerability and dosing flexibility rather than trying to out-Muscle incumbents on pure weight-loss magnitude. The second-order effect is that broader obesity leadership is becoming less about a single winner and more about a multi-node ecosystem where amylin-based approaches can fragment share across clinicians, payers, and patient segments.

For competitors, the biggest loser is any program that needs very high dose escalation to look compelling; those assets now face a valuation multiple reset as investors start discounting GI burden, discontinuation risk, and slower titration as commercial liabilities. The near-term supply-chain angle is also important: if amylin/combination adoption accelerates, manufacturing capacity and injection-device availability become gating factors, which can create unplanned winners among contract manufacturers and device suppliers while squeezing smaller biotechs with weaker supply commitments.

The main catalyst window is the next 1-3 months, when conference enthusiasm either translates into sell-side model upgrades or fades if no clearer dose-response and durability signal emerges. The tail risk is that the market may be over-assigning probability to a broad obesity re-rating before Phase 3 execution de-risks; if tolerability or dropout data disappoints, the premium for “next-gen” differentiation could compress quickly. Conversely, if the field adopts a minimum-effective-dose framework, it materially improves the addressable population and payer willingness to fund chronic treatment.

Contrarian angle: the current debate may be underestimating how much commercial success will depend on sequencing and combination strategy rather than monotherapy efficacy alone. That creates an option value embedded in platforms with multiple shots on goal, but it also means investors should be selective about paying up for single-asset obesity stories unless they have clear evidence of durable differentiation and manufacturing scale.

Key Decisions for Investors

• Add to ZLDPY on conference-driven weakness rather than strength; use a 4-8 week window to build exposure if the stock retraces on profit-taking, with upside tied to the market repricing amylin as a platform rather than a single molecule.
• Pair trade: long ZLDPY / short a higher-multiple obesity name with more dose-escalation dependency and less clear tolerability differentiation; target a 3-6 month horizon where dose-window concerns can widen dispersion.
• Buy short-dated call spreads on ZLDPY into the next clinical/data milestone; structure for 2:1 to 3:1 upside if the market starts pricing a broader obesity platform rerating, with limited premium at risk.
• If you want lower beta exposure to the theme, express it through contract manufacturing or device suppliers with obesity/manufacturing leverage rather than pure biotech names; those beneficiaries can re-rate on capacity bottlenecks even if drug valuation multiples stall.
• Set a hard risk control: if follow-up data shifts the conversation back toward tolerability or discontinuation issues, reduce obesity exposure across the basket quickly, as the re-rating in this segment can reverse in days, not quarters.